PURPOSE: Several diagnostic trials have indicated that the combined use of (18)F-fluoroethyl-L: -tyrosine (FET) PET and MRI may be superior to MRI alone in selecting the biopsy site for the diagnosis of gliomas. We estimated the cost-effectiveness of the use of amino acid PET compared to MRI alone from the perspective of the German statutory health insurance. METHODS: To evaluate the incremental cost-effectiveness of the use of amino acid PET, a decision tree model was built. The effectiveness of FET PET was determined by the probability of a correct diagnosis. Costs were estimated for a baseline scenario and for a more expensive scenario in which disease severity was considered. The robustness of the results was tested using deterministic and probabilistic sensitivity analyses. RESULTS: The combined use of PET and MRI resulted in an increase of 18.5% in the likelihood of a correct diagnosis. The incremental cost-effectiveness ratio for one additional correct diagnosis using FET PET was €6,405 for the baseline scenario and €9,114 for the scenario based on higher disease severity. The probabilistic sensitivity analysis confirmed the robustness of the results. CONCLUSION: The model indicates that the use of amino acid PET may be cost-effective in patients with glioma. As a result of several limitations in the data used for the model, further studies are needed to confirm the results.
PURPOSE: Several diagnostic trials have indicated that the combined use of (18)F-fluoroethyl-L: -tyrosine (FET) PET and MRI may be superior to MRI alone in selecting the biopsy site for the diagnosis of gliomas. We estimated the cost-effectiveness of the use of amino acid PET compared to MRI alone from the perspective of the German statutory health insurance. METHODS: To evaluate the incremental cost-effectiveness of the use of amino acid PET, a decision tree model was built. The effectiveness of FET PET was determined by the probability of a correct diagnosis. Costs were estimated for a baseline scenario and for a more expensive scenario in which disease severity was considered. The robustness of the results was tested using deterministic and probabilistic sensitivity analyses. RESULTS: The combined use of PET and MRI resulted in an increase of 18.5% in the likelihood of a correct diagnosis. The incremental cost-effectiveness ratio for one additional correct diagnosis using FET PET was €6,405 for the baseline scenario and €9,114 for the scenario based on higher disease severity. The probabilistic sensitivity analysis confirmed the robustness of the results. CONCLUSION: The model indicates that the use of amino acid PET may be cost-effective in patients with glioma. As a result of several limitations in the data used for the model, further studies are needed to confirm the results.
Authors: T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch Journal: Eur J Nucl Med Mol Imaging Date: 2006-11 Impact factor: 9.236
Authors: Frank W Floeth; Dirk Pauleit; Michael Sabel; Gabriele Stoffels; Guido Reifenberger; Markus J Riemenschneider; Paul Jansen; Heinz H Coenen; Hans-Jakob Steiger; Karl-Josef Langen Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss Journal: Clin Cancer Res Date: 2004-11-01 Impact factor: 12.531
Authors: José L Burgos; Julia A Gaebler; Steffanie A Strathdee; Remedios Lozada; Hugo Staines; Thomas L Patterson Journal: PLoS One Date: 2010-06-30 Impact factor: 3.240
Authors: Karl-Josef Langen; Frank W Floeth; Gabriele Stoffels; Kurt Hamacher; Heinz H Coenen; Dirk Pauleit Journal: Z Med Phys Date: 2007 Impact factor: 4.820
Authors: Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier Journal: J Nucl Med Date: 2004-08 Impact factor: 10.057
Authors: Frederik A Verburg; Florian F Behrendt; Felix M Mottaghy; Alexander Heinzel Journal: Eur J Nucl Med Mol Imaging Date: 2013-10-11 Impact factor: 9.236
Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Tineke van de Weijer; Martijn P G Broen; Rik P M Moonen; Ann Hoeben; Monique Anten; Koos Hovinga; Inge Compter; Jochem A J van der Pol; Cristina Mitea; Toine M Lodewick; Arnaud Jacquerie; Felix M Mottaghy; Joachim E Wildberger; Alida A Postma Journal: Diagnostics (Basel) Date: 2022-05-11
Authors: Vincent Dunet; Anastasia Pomoni; Andreas Hottinger; Marie Nicod-Lalonde; John O Prior Journal: Neuro Oncol Date: 2015-08-04 Impact factor: 12.300
Authors: Alexander Heinzel; Dirk Müller; Sareh Said Yekta-Michael; Garry Ceccon; Karl-Josef Langen; Felix M Mottaghy; Martin Wiesmann; Martin Kocher; Elke Hattingen; Norbert Galldiks Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300
Authors: Giorgio Treglia; Barbara Muoio; Gianluca Trevisi; Maria Vittoria Mattoli; Domenico Albano; Francesco Bertagna; Luca Giovanella Journal: Int J Mol Sci Date: 2019-09-20 Impact factor: 5.923